American Medical AssociationOlaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

From JAMA Network Open comes this conclusion: “In this study, the benefit associated with olaparib was reduced, eliminated, or inferior in specific subgroups of patients when treatment outcomes were compared with a more active standard of care, ie, cabazitaxel. While treatment with olaparib was associated with superior rPFS in patients with BRCA1/2 variants, those with […]

American Society of Clinical OncologyRadiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer

Directly from this Journal of Clinical Oncology Original Report: “Among men randomly assigned to receive ADT + RT + docetaxel versus ADT + RT, significantly less RT-induced cancers were observed. The treatment effect of adding docetaxel to ADT + RT on overall survival in men with a prostate-specific antigen (PSA) < 4 ng/mL was driven […]

American Medical AssociationEffects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance

In this clinical trial, the authors attempt to answer the question of whether a high-intensity interval training program can improve cardiorespiratory fitness and delay the biochemical progression of prostate cancer in patients who are undergoing active surveillance. One group was asked to complete 12 weeks of thrice-weekly, supervised aerobic sessions on a treadmill at 85% […]

Cancer Therapy AdvisorControversy Prompts Another Update to the NCCN Guidelines for Prostate Cancer

Bowing to criticism from doctors, the National Comprehensive Cancer Network (NCCN) has again updated its guidelines for prostate cancer. The previous update, released this past September, had changed the recommendation about active surveillance for low-risk prostate cancer to state that active surveillance was no longer the “preferred” management option for patients with low-risk prostate cancer […]

Cancer Therapy AdvisorDocs Disagree with Update to NCCN Guidelines for Prostate Cancer

The updated NCCN guidelines no longer say that active surveillance is “preferred” for low-risk prostate cancer, prompting some physicians to claim this recommendation may encourage overtreatment and is a “step back” from progress made over the last decade, which has been defined by active surveillance as the preferable care option for most low-risk localized prostate […]